Nanogroup (NNG.WA) Action Cours

NanoGroup SA generates revenue through its advanced biotechnological projects focused on cancer prevention, early diagnosis, and targeted therapies. The company's portfolio includes NanoVelos, which develops drug delivery systems for oncologic medicines, and NanoSanguis, which creates artificial blood for accident victims and an organ preservation system called Organ farm. NanoThea specializes in early cancer detection technology. These products are sold to medical institutions, research facilities, and healthcare providers seeking innovative solutions in oncology and organ preservation. The firm's revenue streams come from licensing agreements and direct sales of its biotechnological solutions. NanoVelos targets pharmaceutical companies needing optimized drug delivery, while NanoSanguis serves emergency medical services and trauma centers requiring artificial blood and organ preservation. NanoThea's early cancer detection systems are purchased by diagnostic centers and hospitals aiming to improve patient outcomes through early intervention. NanoGroup SA's business model relies on the commercialization of its R&D projects, with each brand addressing specific medical needs. The company's focus on cancer-related technologies and organ preservation positions it as a key supplier in the biotech sector, serving healthcare providers and research organizations that require cutting-edge medical solutions.